Genetic association studies of symptoms, comorbidity and outcome in bipolar disorder and schizophrenia by Hukic, Dzana Sudic
From THE DEPARTMENT OF MOLECULAR MEDICINE AND 
SURGERY 
Karolinska Institutet, Stockholm, Sweden 
GENETIC ASSOCIATION STUDIES OF 
SYMPTOMS, COMORBIDITY AND 
OUTCOME IN BIPOLAR DISORDER AND 
SCHIZOPHRENIA 
Dzana Sudic Hukic 
 
Stockholm 2016 
 
 Cover image by Emil Hukić, 2016 
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by E-print AB 2016 
© Dzana Sudic Hukic, 2016 
ISBN 978-91-7676-246-2 
GENETIC ASSOCIATION STUIDES OF SYMPTOMS, 
COMORBIDITY AND OUTCOME IN BIPOLAR 
DISORDER AND SCHIZOPHRENIA 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Dzana Sudic Hukic 
Principal Supervisor: 
MD, PhD Urban Ösby 
Karolinska Institutet 
Department of Neurobiology, Care, Sciences and 
Society 
Division of Family medicine 
 
Co-supervisors: 
Associate Professor Catharina Lavebratt 
Karolinska Institutet 
Department of Molecular Medicine and Surgery 
 
Professor Martin Schalling 
Karolinska Institutet 
Department of Molecular Medicine and Surgery 
 
Associate Professor Louise Frisén 
Karolinska Institutet 
Department of Clinical Neuroscience 
 
Opponent: 
Evangelos Vassos 
Kings College 
Department of Social, Genetic & Developmental 
Psychiatry 
 
Examination Board: 
Professor emeritus Ulf Adamson 
Karolinska Institutet 
Department of Clinical Sciences 
Danderyd Hospital 
 
Professor Stephanie Le Hellard 
University of Bergen, Norway 
Department of Clinical Sciences 
 
Professor Anders Tingström 
Lund University 
Department of Clinical Sciences 
 
 

  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my beloved family, especially my father who left us too early   
       
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
ABSTRACT 
 
Schizophrenia and bipolar disorder are complex brain disorders. Research has focused on 
applying brain research to understand the etiology, as well as clinical research to improve 
treatment, prognosis and progression. Schizophrenia and bipolar disorder are not lethal in and 
of themselves, but suicide and the presence of associated physical illnesses are of great 
concern, since these are the major causes of shortened life in afflicted individuals. In 
particular, the prevalence of type 2 diabetes and cardiovascular disease are twice as great in 
schizophrenia and bipolar disorder. By shifting the focus to underlying, sometimes comorbid 
causes, it is possible to increase knowledge of morbidity and mortality in cardiovascular 
disease, and thus improve the prognosis and progression for individuals with schizophrenia 
and bipolar disorder. Another interesting strategy for better understanding such complex 
disorders is to limit examination to symptoms in order to distinguish the genetics of the 
symptoms from the disorder itself. Genetic association studies are often used to investigate 
complex disease. The aim of this thesis was to investigate genetic associations between gene 
variants and metabolic risk factors in schizophrenia and bipolar disorder patients. An 
additional aim was to investigate known psychiatric risk genes in the dopamine system and 
their association to cognitive function. 
In Study I, D-amino acid oxidase activator gene (DAOA) and catechol-O-methyltransferase 
gene (COMT) were analyzed for allelic association to cognitive dysfunction in bipolar 
disorder patients. In Studies II-V, common metabolic risk gene variants were analyzed for 
allelic association to metabolic risk factors in schizophrenia and bipolar disorder patients, and 
to disorders per se. In Study VI, metabolic risk variants were analyzed for possible 
association to high-sensitive troponin T levels, which is a sensitive biomarker of 
cardiovascular damage in patients with acute coronary syndrome. 
In study I, single nucleotide polymorphisms in D-amino acid oxidase activator gene (DAOA) 
and catechol-O-methyltransferase gene (COMT) were associated to cognitive dysfunction in 
bipolar disorder patients. Data also suggest interaction between these genes. In studies II-V, 
single nucleotide polymorphisms in common metabolic risk genes: insulin-like growth factor 
II mRNA binding protein 2 (IGF2BP2), neurogenic locus notch homolog 2 (NOTCH2), 
thyroid adenoma associated (THADA), wolfram syndrome 1 (WFS1), purinergic receptor 
P2X, ligand-gated ion channel, 7 (P2RX7), and melatonin receptor 1B (MTNR1B) were 
associated with increased fasting plasma glucose in schizophrenia. Peroxisome proliferator-
activated receptor delta gene (PPARD) was associated with schizophrenia independent of 
glucose levels. Single nucleotide polymorphisms in common metabolic risk genes: 
calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2), melanoma inhibitory 
activity family, member 3 (MIA3), purinergic receptor P2X, ligand-gated ion channel, 7 
gene (P2RX7), muscle RAS oncogene homolog gene (MRAS), SMAD family member 3 
gene (SMAD3), peroxisome proliferator-activated receptor delta gene (PPARD), melatonin 
receptor 1B gene (MTNR1B), neurogenic locus notch homolog 2 gene (NOTCH2), HNF1 
homeobox B gene (HNF1B) were associated with increased waist circumference in 
schizophrenia patients. Peroxisome proliferator-activated receptor delta gene (PPARD), 
melatonin receptor 1B gene (MTNR1B), neurogenic locus notch homolog 2 gene 
(NOTCH2), and homeobox B gene (HNF1B) were associated with schizophrenia 
irrespective of waist circumference. A genetic overlap between schizophrenia and bipolar 
disorder was identified through an association between melatonin receptor 1B gene 
(MTNR1B) and increased fasting plasma glucose also in bipolar disorder patients. Neurogenic 
locus notch homolog 2 gene (NOTCH2) was associated to bipolar disorder per se. In study 
VI, melatonin receptor 1B gene (MTNR1B) and neurogenic locus notch homolog 2 gene 
(NOTCH2) were associated with high-sensitive troponin T levels in schizophrenia women.  
Our genetic findings regarding D-amino acid oxidase activator gene (DAOA) and catechol-
O-methyltransferase gene (COMT) are in line with the dopamine hypothesis of cognitive 
function. Single nucleotide polymorphisms that increase metabolic risk in the general 
population are associated with elevated plasma glucose and increased waist circumference 
among schizophrenia and bipolar disorder patients, as well as with schizophrenia and 
bipolar disorder per se. The melatonin receptor 1B gene (MTNR1B) –dependent 
vulnerability for elevated fasting plasma glucose levels is evident in both schizophrenia and 
bipolar disorder. Neurogenic locus notch homolog 2 gene (NOTCH2) is associated to both to 
schizophrenia and bipolar disorder type 1 per se. These findings may reflect increased 
metabolic genetic vulnerability in schizophrenia and bipolar disorder patients, as well as 
common genetics between type 2 diabetes mellitus and these psychiatric disorders. In 
addition, in women with schizophrenia, there is a possible metabolic genetic component 
affecting high-sensitive troponin T levels, a biomarker for cardiovascular damage in 
individuals with acute coronary syndrome (chest pain). 
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1 PSYCHIATRIC DISORDERS 
 
1.1 PSYCHIATRIC DISORDERS IN GENERAL 
Psychiatric disorder (PD) is considered a major public health problem, rated as one of the top 
ten disabling conditions worldwide (1). Every fourth individual is or will be affected during 
some point in their life. In addition, one-third meet the criteria for multiple psychiatric 
diagnoses (2), and also demonstrate a high presence of other somatic disorders (3-5). PD 
patients have a higher risk of dying prematurely. Cardiovascular and circulatory diseases are 
responsible for the highest number of lost life years in PD (5). The cause of PD has not yet 
been discovered, which is in itself the greatest research challenge – along with the need for 
better treatment and improved drugs. Moreover, poor attitudes and discrimination towards 
people with PD still results in social stigma. This stigma is a long-lasting health and social 
burden that requires more research, resources and public awareness. By generating new 
knowledge, we may also reduce the stigma. 
This thesis focuses on severe psychiatric disorders, particularly schizophrenia (SCZ) and 
bipolar disorder (BD), as well as related disorders and symptoms. Genetics represents one of 
the main explanations for why we become mentally ill. All studies in this thesis are based on 
genetic analysis. 
 
1.2 SCHIZOPHRENIA AND BIPOLAR DISORDER 
Schizophrenia (SCZ) and bipolar disorder (BD) are common, severe and essentially lifelong 
brain disorders. The prevalence in the population for SCZ and BD is about 1% each, 
irrespective of culture and country variations (6, 7). The disorders usually appear in the late 
teens or early adulthood (8, 9), although there are cases reported in the early, as well as late 
years of life. 
The classical clinical distinction between these two disorders was based on Emil Kraepelins 
theory when he distinguished between manic-depressive disorder and madness. However, 
both SCZ and BD patients experience mood swings, cognitive impairment and psychotic 
features - all of which might have fallen into the category of madness according to Kraepelin. 
Therefore, his clinical division between SCZ and BD is coming under increasing scrutiny as 
growing genetic and biological evidence identifies overlapping genes and phenotypes. 
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1.3 CLINICAL SYMPTOMS 
1.3.1 Schizophrenia 
The word schizophrenia comes from the Greek “σχιζοφ (schizo) ρένεια (phrenia) and means 
split mind. Persons suffering from SCZ have a distorted perception of reality (losing touch 
with reality) that includes psychotic (or positive) symptoms such as hallucinations 
(perceptions, hearing or seeing things, without external stimuli) and delusions (they strongly 
believe in something despite evidence to the contrary) that are present in the acute phase of 
the disorder and are core features of SCZ. The clinical picture is broad and includes a number 
of additional symptoms including cognitive impairment typically present in schizophrenia 
patients, diminished feelings and emotions, as well as loss of interest in daily activities that 
may persist over time, often becoming chronic. 
1.3.2 Bipolar disorder or manic-depressive illness 
BD or manic-depressive illness is characterized by disturbed balance in mood. Persons with 
BD experience depressive and manic episodes. In between episodes, bipolar patients recover 
from the symptoms and are in a more stable condition. How frequently and how quickly the 
patients shift between the different episodes depends on the severity and subtype of BD. 
During manic episodes, persons with BD experience increased self-esteem, reduced sleep, 
and have a lot of energy and ideas, often with a lack of insight as to the following 
consequences. On the contrary, depressed episodes include reduced self-esteem and inability 
to feel pleasure, as well as increased sleep and less energy, and also more serious thoughts of 
suicide. These may seem like common emotions, feelings and thoughts that we all 
experience, but for BD sufferers the feelings and emotions are heightened and more tangible, 
and affect everyday life to a great extent.   
 
1.4 DIAGNOSIS 
The diagnosis of SCZ and BD is based on clinical symptoms by observing behavior, feelings, 
and thoughts. Even today, there are no tests based on genetics, biochemistry, or brain imaging 
analysis that can assist the diagnosis process. 
1.4.1 Schizophrenia 
In the Diagnostic and Statistical Manual of Mental Disorders (DSM), which contains 
classifications and criteria for the diagnosis of psychiatric conditions from the American 
Psychiatric Association, schizophrenia is classified under the chapter "Schizophrenia 
Spectrum And Other Psychotic Disorders". The subtypes of schizophrenia are based on the 
symptoms that dominate (paranoid, disorganized, catatonic, undifferentiated and residual). 
Patients in this thesis have been diagnosed according to the DSM 4th Edition (DSM-IV) (10). 
According to DSM-IV, a person needs to fulfill the following diagnostic criteria for the SCZ 
diagnosis: two (or more) episodes of delusions, hallucinations, disorganized speech, 
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disorganized or catatonic behavior, and negative symptoms (i.e. affective flattening), each 
present for a 1-month period (or less if treated with success). Additional criteria involve 
social dysfunction, duration of the symptoms, and also exclusion of possible use of drugs and 
alcohol, alternatively endocrine disturbance. Schizophrenia is a spectrum of psychotic 
disorders rather than a distinct condition. Other psychotic disorders include schizoaffective 
disorder, delusional disorder and psychosis not otherwise specified (NOS). 
1.4.2 Bipolar disorder 
BD is classified under the chapter “Mood Disorders” in the DSM-IV (10). Mania or 
hypomania is a defining criterium for bipolar disorder diagnosis. Criteria for manic episodes 
include abnormal irritable mood during a period of 1 week (or any period if there is a need 
for hospitalization), and three (or more) of the following symptoms: inflated self-esteem, 
decreased need of sleep, talkativeness, racing thoughts, distractibility, increase in goal-
directed activity and excessive involvement in activities with a high risk of painful 
consequences. Additionally, marked deterioration in daily activities and relationships, also 
exclusion of possible use of drugs and alcohol induced symptoms. During the manic 
episodes, many patients show cognitive impairment. There is evidence that cognitive 
impairment may persist over time, even between active episodes (11, 12), thus also affect 
long-term social functioning. 
 
1.5 ETIOLOGY  
The cause of the psychiatric disorders is, to a large extent, unknown. Genetic and 
environmental risk factors stand out. A multitude of genetic studies have proposed a number 
of candidate genes. However, the mechanisms by which genetic and environmental factors 
interact, affect and reflect the neurobiology and symptoms of psychiatric disorders remains to 
be discovered. 
1.5.1 Neurotransmitter hypotheses 
Neurotransmitters are chemical substances that transmit signals from one neuron (nerve cell) 
to another neuron. There are hypotheses built around known abnormal neurotransmission and 
symptoms in psychiatric disorders. Some sustained hypotheses are listed below and are based 
on dopamine (DA), and glutamate (Glu) in SCZ. Genetics underlying the signaling of these 
neurotransmitters is thus of substantial interest. 
1.5.1.1 The dopamine hypothesis 
The leading hypothesis of SCZ is dysfunctional DA signaling (13, 14). DA is produced in the 
brain regions called the substantia nigra and ventral tegmental area, and transported via 
dopaminergic pathways to different regions of the brain. Several studies demonstrate that 
drugs that induce DA release also induce psychotic symptoms, while, on the contrary, drugs 
that block DA signaling reduce psychotic symptoms, which is the main evidence suggesting 
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DA’s involvement in the etiology of SCZ (15, 16), and the DA-receptors as targets in the 
treatment of psychotic symptoms. 
The brain region prefrontal cortex (PFC) has also been implicated in the hypothesis of SCZ. 
In this region, the DA levels are reduced. Studies show reduced prefrontal cerebral blood 
flow (CBF) in SCZ individuals (17, 18). In addition, DA metabolite levels in cerebrospinal 
fluid (CSF) correlates with prefrontal CBF (18), indicating low DA in PFC. The PFC is an 
important region for cognitive function, thus this proposes the involvement of DA in 
cognitive functioning. 
Genes that influence DA are of interest to study. Catechol-O-methyltransferase (COMT) is an 
enzyme that degrades DA. One functional SNP (SNP definition see page 28) of the COMT 
gene has been of special interest. This SNP (Val158Met or rs4680) has been reported to 
affect the production of the COMT enzyme, thereby regulating the degradation of dopamine. 
If the “Met” variant is present, the enzyme function is lower and DA level is higher (19). 
Higher DA level is associated with psychotic symptoms. COMT has also been implicated in 
the neurobiology of cognition. The “Met” variant associated with better performance on 
working memory in SCZ, and in the general population (more functioning brain) (20), thus 
also increases the risk for SCZ. Furthermore, COMT has been reported to influence the 
performance on facial emotion recognition in BD (21). 
1.5.1.2 The glutamate hypothesis 
Glu signaling is important for neurotransmission, plasticity, memory and learning (22). 
Blocking N-methyl-D-aspartate receptors (NMDAR) is reported to induce schizophrenia-like 
symptoms (23) and altered NMDA receptors have been associated with reduced memory 
(24). Lower Glu plasma levels have been detected in SCZ and BD patients at the onset of the 
disorders, indicating an impaired Glu system at an early stage of the illness (25). High 
concentration of Glu may induce manic symptoms.  
The DAOA (D-amino acid oxidase activator or G72) gene is one of the interesting genes 
related to Glu signaling. The DAOA gene codes D-amino acid oxidase activator (DAOA) 
that may influence the function of D-amino acid oxidase (DAO), which is an enzyme that 
catalyzes the conversion of D-DOPA into L-DOPA (26) that is a precursor of DA. DAOA 
also influences the function of D-serine, which activates NMDA receptors (27). 
There is also support for combined genetic effects of glutamatergic and dopaminergic 
pathways on cognitive functioning (28). 
 
1.6 GENETICS OF PSYCHIATRIC DISORDERS IN GENERAL 
Genetic differences represent one of the main explanations for why we become mentally ill. 
SCZ and BD are highly heritable disorders, with heritability estimates as high as 85% (29, 
30). 
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The risk of getting ill increases with shorter genetic distance to the affected person (31). 
Identical twins share same DNA, thus may share the highest risk of getting ill. If it were only 
genetics that influenced the development of the disorder, both identical twins would be sick. 
This is not the case, the genetic penetrance does not alone decide whether we get sick or not.  
In addition to genetic variation, environmental factors such as birth complications (32), 
history of infections (33), drug use (16), and epigenetics (34) may influence susceptibility to 
psychiatric disorders. Genetics and environmental factors work together in a very complex 
way, not yet understood.  
From large genetic studies, such as Genome Wide Association Studies (GWAS) that examine 
associations between a large number of common SNPs and diseases, we have learned that a 
large number of common gene variants are important for the development of SCZ and BD or 
traits like cognition (polygenic inheritance), although each variant has a small effect size. In 
addition, we have learned that identified genetic risk variants together explain only a small 
fraction of the heritability (35). What is more, one gene may also affect more than one 
disorder (pleiotropy). For example, SCZ and BD patients share substantial genetic risk 
components (36). Clinically, SCZ and BD are distinct disorders, but the biological distinction 
does not necessarily follow the clinical division.  
Results from genetic studies also lack information of how genes affect disorders. As of yet, 
the relevance of genetic results has not yet been taken into consideration in clinical settings, 
and such results also still lack clinical value regarding disease onset and outcome. 
 
1.7 TREATMENT 
Antipsychotic drugs are the main treatment for SCZ and schizoaffective disorder patients. All 
antipsychotics act on the dopaminergic system by blocking the release of DA. Clozapine 
affects a wide range of receptors and has a clinical indication for cases that are resistant to 
treatment with other antipsychotics. Lithium and other mood stabilizers are the main 
treatments for BD type 1 patients, often in combination with antipsychotics as 
complementary therapy. Although there are proposed mechanisms of lithium action via the 
glutamatergic system (37), its specific function is still unclear. In addition to medications, 
other measures such as psychosocial interventions are needed. In some cases it can take 
several years before the correct diagnosis and treatment (right drug and dose) is established. 
Variations between patients in drug response are common.  
1.7.1 Side-effects of antipsychotics 
Antipsychotics are known to have harmful effects. First-generation antipsychotics (FGAs) or 
typical antipsychotics are known to have side effects such as extrapyramidal symptoms (EPS) 
that are movement disorders, and include muscle contractions, rigidity and irregular 
movements (38). Although the second-generation antipsychotics (SGAs) have been improved 
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and offer patients a better experience, the SGAs – in particular clozapine and olanzapine – 
have contributed to increased cardiovascular disease (CVD) risk, which ultimately has 
negative effect on the long-term prognosis. 
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2 SCHIZOPHRENIA, BIPOLAR DISORDER & METABOLIC 
COMORBIDITIES 
 
Mentally ill individuals often have metabolic disorders. There is insufficient treatment of 
severe mentally ill (SMI) individuals concerning somatic illness, which affects prognosis and 
outcome in a negative way. Lack of knowledge regarding how to treat SMI may result in 
inadequate communication in health care and greater focus on the primary (mental) diagnosis 
that shifts attention away from somatic problems. A holistic view of the patient is needed to 
identify the presence of somatic disorders early on for improved treatment and prognosis of 
the patient.   
One of the major issues in SMI is CVD. Although death from suicide is markedly increased 
in SCZ and BP, CVD is the leading cause of death in this patient group (3, 4). There are two 
times more deaths in SCZ and BD patients than the numbers reported for the general 
population (39). In Sweden, the life expectancy of persons suffering from SCZ is reduced by 
15 to 17 years (40). This reduced life expectancy in SCZ is mainly explained by increased 
CVD comorbidity and mortality. Similar findings have been reported for BD patients (4, 41). 
Further knowledge about CVD in SCZ and BD is strongly warranted. 
 
2.1 RISK FACTORS FOR CARDIOVASCULAR DISEASE  
In addition to risk factors such as age, gender and genetic predisposition (42-44), some risk 
factors are often emphasized when referring to CVD risks. These are presented below. 
2.1.1 Diabetes and metabolic disturbances 
Diabetes mellitus (DM) and metabolic disturbances such as increased weight, elevated fasting 
plasma glucose (FPG), elevated blood pressure, and imbalance in blood lipids, are all 
established and well known risk factors that increase the risk for CVD. Moreover, smoking, 
physical inactivity, poor diet and stress are risk factors for DM, especially type 2 diabetes 
mellitus (T2DM).  
T2DM is a major and growing public health concern worldwide for all ages, with a 
prevalence reported to be around 8.5% in Europe in 2013 (44, 45). T2DM represents the 
majority of all diabetes cases. It usually manifests in adults when the body’s response to 
insulin becomes impaired (46). The lifetime risk of developing T2DM is over 30%, and 
higher for women than men. Individuals diagnosed with T2DM have a reduced lifespan (47, 
48).  Increased levels of FPG relative to age are three times more frequent in patients with 
psychotic disorders than in population controls (49). 
Despite the fact that the global population is aging and these disorders are associated with an 
aging population, which is also an explanation for increased mortality from CVD (with some 
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geographical variations), being overweight persists as a major risk component of T2DM (44), 
and thereby also CVD. SCZ individuals are two times more likely to be overweight than the 
general population (50). SCZ individuals also have an unhealthier lifestyle including poorer 
diet and less physical activity (51, 52).  
Individuals with a positive family history of T2DM have an increased storage of fat and risk 
for obesity when compared to individuals without T2DM in the family (42, 43). T2DM is a 
predictor of increased mortality in SMI individuals (53). Furthermore, SCZ and BD are 
disorders that have hereditary components in common (36). In this thesis, the increased CVD 
mortality in SCZ and BD is hypothesized to be an effect, in part, of metabolic risk genes, 
which might overlap between SCZ and BD, and also with the general population. 
2.1.1.1 Etiology of type 2 diabetes 
The cause of T2DM is based on insulin resistance (cells in the body no longer respond to 
insulin). This condition results in increased blood glucose levels, which is a key clinical 
characteristic of T2DM (46). The oral glucose tolerance test (OGTT) is a clinical T2DM 
diagnostic test. Another test involves measuring C-peptide in the blood, which is a byproduct 
during insulin production. One insulin molecule corresponds to one C-peptide molecule, 
making C-peptide a biomarker of insulin production. 
When we eat, our glucose concentration (sugar in the blood) increases, and so does the 
production of insulin in the pancreas, which helps cells in the body utilize glucose. In 
addition to the pancreas (where the beta cells produce insulin), the liver has a glucose-related 
task. In order to maintain glucose homeostasis in the body, the liver absorbs excess glucose in 
the blood, and stores it as glycogen, (glucoseàglycogen = glycogenesis). Once the glucose 
level is low (i.e. during the night while we sleep), the liver releases glucose reserves, 
(glycogenàglucose = glycogenolysis) to maintain glucose homeostasis.  
The abdominal (stomach) fat is the most harmful kind of fat. Accumulation may contribute to 
excess fat in the liver, and impair the liver’s glucose-related function (54) – causing increased 
level of FPG in T2DM individuals (55). Waist circumference is a convenient measure of 
excess abdominal fat (56, 57), and high values indicates metabolic abnormalities, regardless 
of weight (58-60).  
2.1.1.2 The International Diabetes Federation (IDF) criteria  
The International Diabetes Federation (IDF) has proposed criteria for reference (cut-off) 
values that constitute risk factors for T2DM. The IDF criteria are followed in the studies of 
this thesis. The cut-off level for elevated FPG level is defined as FPG ≥5.6 mmol/L, and for 
increased waist circumference ≥80 cm for women and ≥94 cm for men. 
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2.1.2 Antipsychotic and lithium induced metabolic disturbance  
Antipsychotic drugs are frequently mentioned in the context of metabolic disturbances, 
especially increased weight.  One possible mechanism behind the weight gain is through up-
regulation of histamine receptors (61) since histamine is a neurotransmitter known to increase 
appetite. There are also indications that antipsychotic medication may affect insulin 
production directly, without significant weight change (62, 63).  
Clozapine and olanzapine are two of the antipsychotics that are most often associated with 
increased weight. Clozapine treated rats (without significant weight change) had increased 
expression in the liver of glucose-6-phosphatase (G6Pase) which encodes an enzyme that is 
involved in glycogenesis and glycogenolysis (62). This is in line with the hypothesis that 
increased weight gain from clozapine may occur through reduced hepatic glucose-related 
metabolism and increased glucose levels.  
In addition, studies of drug free and drug naïve (untreated) patients indicate increased levels 
of visceral fat deposition (64). What is more, an increased prevalence of T2DM has been 
reported in drug naïve psychosis patients (64-67), and in healthy relatives of people with SCZ 
(68), which suggests that there is a genetic predisposition to metabolic disturbances in SCZ 
patients.  
Antipsychotics are used much less in treatment for BD patients compared to SCZ patients, 
despite the fact that BD patients have a similarly doubled mortality from CVD (4, 41). 
Lithium has been associated with increased weight, and thereby a risk of metabolic 
abnormalities (69). However, a differential effects of lithium in obese and non-obese patients 
has been reported. Patients who are already obese put on more weight, while non-obese 
patients do not show the same weight gain during lithium treatment (70). This supports the 
hypothesis that the genetic overlap between SCZ and BD may also include shared metabolic 
vulnerability beyond drug impact. 
2.1.3 Psychiatric disease as a risk factor  
Psychosis itself has been reported as an independent CVD risk factor (71). Severity of BD 
(manic-depressive illness) has been associated with metabolic disturbances (72, 73). 
Although it is well known that PD increases the risk of T2DM, this correlation might be 
operating in both directions, T2DM might also increase the risk for PD, which seems to 
receive less attention. Risk of PD (mood and anxiety disorders) is higher among persons 
with DM (74). The existence of diabetes doubles the odds for depression (75). SCZ and 
T2DM share familial risk factor; positive family history of psychosis is associated with 
positive family history of T2DM in SCZ patients (76), which supports the genetics 
underlying the increased frequency of T2DM among SCZ patients. There is also a genetic 
risk region that overlap between SCZ and T2DM (77). 
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2.2 GENETICS OF TYPE 2 DIABETES 
T2DM is a complex chronic disorder with a slow progression and long duration. Both genes 
and environmental factors contribute to the development of T2DM. The genetic inheritance is 
supported by genetic studies of identical twins that estimated a concordance rate of 25% for 
T2DM, and of over 60% for impaired glucose tolerance (78, 79). Genetic findings explain 
only a small portion of the T2DM heritability. 
GWAS have generated several loci containing genes and common SNPs with association to 
T2DM and impaired glucose traits. Several of the genes and SNPs with associations to 
metabolic traits presented in this thesis have reached the GWAS level of statistical 
significance in previously published studies, although the effect sizes for the most GWAS 
associations are small and limited. There are some proposed mechanisms of genetic action: 
impaired insulin processing, lower insulin secretion, reduced insulin sensitivity, and defects 
in early insulin secretion. Most SNPs associated to T2DM indicate a primary defect in beta 
cells (80).  
In this thesis, increased FPG in SCZ and BD patients shows an association to the SNP 
rs10830963 in the MTNR1B gene. The rs10830963 with the top signal to FPG has, in large 
GWAS, been associated with elevated FPG levels, impaired beta cell function, and T2DM 
(81-83). This gene codes for melatonin receptor 1B that is expressed in beta cells. T2DM 
patients tended to have increased expression of this receptor in beta cells (84). The effect of 
rs10830963 on impaired glucose takes place probably through an initial phase of glucose-
stimulated insulin release (82-84), suggesting that MTNR1B impairs the early insulin 
secretion. 
Melatonin also regulates the circadian rhythm. There is evidence in the literature for a link 
between circadian genes and T2DM (85). Moreover, it is not uncommon that PD patients 
have disturbed sleep.  
The metabolic risk gene, NOTCH2, presented in this thesis that might be considered as a new 
finding as it has not been reported previously in association to BD, however it is in need of 
replication. Notch signaling is a conservative signaling pathway implicated in many cellular 
functions, although it has been shown to be important for neurogenesis in the adult brain (86). 
A recent study in a mouse model observe that blocked Notch signaling induced an increase in 
dopaminergic neurons (87). Moreover, the presence of an altered Notch2 signaling pathway 
is reported to be associated to suicide victims without PD (88), and additionally it is known 
that death from suicide is greater in SCZ and BD patients compared to the population (4, 89). 
 
2.3 GENETICS OF CARDIOVASULAR DISEASE 
CVD is a complex disease that involves several heart and blood vessel disorders. Most often 
mentioned are myocardial infraction and stroke, which are acute events and depend on the 
loss of blood supply to the heart and brain. The loss of blood supply to the heart and brain is 
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usually due to a blockage in the vessels due to fat accumulation (lipids). Genetic studies on 
CVD risks have focused on lipid metabolism (90-92). One of the most known genes is Apo E 
that codes for Apo E protein. Apo E binds to low-density lipoprotein (LDL) and transports it 
to tissue and cells. Apo E has also been associated with SCZ (93). In one study, SNPs linked 
to SCZ are reported to associate also with CVD risk factors. The majority of those SNPs 
are found with lipid levels, suggesting that lipid metabolism might be involved in 
pathophysiology of SCZ (94).  
Regarding the overlap of SNPs between CVD and T2DM, it is small (95). 
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3   AIMS 
 
The aims of this thesis were to increase the understanding of genetics underlying:  
• cognitive symptoms in BD patients 
• metabolic risk factors in SSD and BD,  
• SSD and BD per se 
• biomarkers of cardiovascular damage in SCZ patients 
 
3.1 SPECIFIC AIMS 
I. To investigate genetic associations between cognitive manic symptoms during 
manic episodes in BD type 1 patients and genetic variants in COMT and DAOA. 
 
II. To test whether reported genetic metabolic risk variants were associated with 1) 
elevated FPG in SSD and 2) whether genetic variants were associated with SSD 
irrespective of glucose levels. 
 
III. To test whether genetic metabolic risk variants, associated with elevated FPG in 
patients with SSD, were associated with elevated FPG in BD.   
 
IV. To investigate whether common genetic metabolic risk variants 1) confer an 
independent risk factor for increased waist circumference in patients with SSD, and 2) 
investigate whether the genetic variants were associated with SSD irrespective of 
waist circumference.  
 
V. To test whether genetic metabolic risk variants, previously associated with elevated 
FPG in patients with BD or SSD, were associated with BD regardless of FPG.  
 
VI. To investigate whether high-sensitive TroponinT levels were associated with common 
genetic metabolic risk variants  reported  for SSD patients. 
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4 MATERIAL AND METHODS 
 
4.1 SUBJECTS 
Ethical approval was obtained from the Stockholm Regional Ethics Committee separately for 
patients and control subjects. All participants gave their informed consent to participate.  
Subjects in this thesis are from four populations, all mainly from the Stockholm region. 
4.1.1 The Swedish study in bipolar disorder 
Unrelated patients above the age of 18 years and diagnosed with BD (with life assessment of 
specific symptoms of mania and depression) were invited to participate. The recruitment of 
patients was performed in specialized outpatients clinics for affective disorders mainly from 
Karolinska University Hospital Huddinge.  
The module for mania in the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) 
(96) was used to register the DSM-IV manic symptoms: elevated mood, irritability, over-
activity, grandiosity, decreased sleep, talkativeness, distractibility, goal-directed behavior, 
thought disorder, and embarrassing behavior (97). The focus was on patients with the most 
severe episode of mania. Additional information was obtained from medical records and also 
from interviews when necessary.  
4.1.2 Swedish Study of Metabolic Risks in Psychosis (SMRP) 
As part of a general medical examination, unrelated patients with long-term psychotic 
disorders, especially schizophrenia, treated in specific psychosis outpatient units, were asked to 
participate in the Swedish Study of Metabolic Risks in Psychosis (SMRP) study. Diagnoses 
were confirmed according to the DSM-IV (10). Schizophrenia was the most common 
diagnosis, other diagnosis represented in the patient material were schizoaffective disorder, 
delusional disorder, psychosis not otherwise specified (NOS), and bipolar disorder (BD).  
Patients were asked to answer to various questions including, somatic health, somatic health 
information in the closely related, smoke and alcohol habits, and employment. Also, psychiatric 
and somatic assessment was compiled together with/by a doctor, containing information about 
Global Assessment of Functioning (GAF), Clinical Global Impression (CGI), onset of the 
disorder and treatment information on drugs and dose, and duration of the treatment. Patients 
received written instructions to fast overnight before leaving blood for analysis. FPG, blood 
pressure, body weight, height, and waist circumference were measured.  
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4.1.3 Stockholm Diabetes Prevention Program (SDPP) 
Control individuals were selected from the Stockholm Diabetes Prevention Program (SDPP) 
(98), comprising 7949 unrelated participants recruited between 1992 and 1998. At inclusion, 
only subjects without known diabetes were enrolled and half of the subjects had ≥ 1 first-degree 
relative with known diabetes. A follow-up was performed 9 to 10 years later (2002-2006) and 
included 5712 subjects (3329 women and 2383 men) (72% of the original participants). At 
follow-up, 997 individuals (17%) had increased FPG (≥ 5.6 mmol/L) including 289 individuals 
(5%) who were diagnosed with T2DM during the period between inclusion and follow-up. 
Data were obtained about weight, height, waist circumference, blood pressure, and FPG both at 
inclusion and at follow-up.  
From the SDPP follow-up sample, control subjects were selected to represent the total SDPP 
cohort for the genetic association study.  
4.1.4 Anonymous blood donors (ABD) 
Anonymous blood donors (ABD) were recruited from Karolinska University Hospital in Solna. 
Information available for the ABD was gender. 
 
4.2 METHODS 
4.2.1 DNA preparation  
For the patients and controls, venous blood was drawn from each individual. DNA was 
extracted according to standard procedures.  
4.2.2 Genetic variations in humans 
The genetic variations in DNA describe and contribute to our uniqueness. Some genetic 
variation can lead to disease - to examine genetic variations we may achieve better 
understanding of complex genetic diseases. Genetic variations vary in size and include; 
duplications, deletions and insertions named copy number variant (CNV). The most common 
genetic difference (>1%) between two human DNAs is Single Nucleotide Polymorphism 
(SNP), which is one base change. Every person has two copies of the same position, called 
alleles (one from each parent) or three possible allele combinations (genotypes) at the specific 
position or SNP, being homozygous (two same alleles) or heterozygous (two different alleles). 
The human DNA counts around 3 billion base pairs. SNPs occur every 300 nucleotides on 
average, so there are about 10 million SNPs. SNPs may be in the gene region (exon or intron) 
or in between genes (non-coding region or intergenic). SNPs may affect the amino acid 
formation (non-synonymous), thus may affect the end product of a protein-coding gene 
(protein) or not affect the amino acid formation (synonymous). In the studies of this thesis, 
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genetic analyses are based on the investigation of genetic associations between 
alleles/genotypes and traits (cognitive impairment/increased FPG/increased waist 
circumference or disorders per se). Many SNPs in this thesis are in non-coding region. 
Alleles that are located close to each other are basically inherited together, they are said to be in 
the linkage disequilibrium (LD) (99). Genetic recombination plays a role in how the alleles are 
organized in the DNA. When genetic recombination occurs between two alleles, the LD 
between alleles are reduced, and the allele organization is changed. 
4.2.2.1 Selection of SNPs 
The SNP selection was hypotheses driven based on previously reported findings.  
Genetic variants with reported GWAS significance (p < 5x10-8) for association with T2DM 
and/or CVD were selected: rs10923931 (NOTCH2), rs7578597 (THADA), rs4607103 
(ADMTS9), rs864745 (JAZF1), rs7961581 (Nearest gene association-TSPAN8/LGR5), 
rs12779790 (Nearest gene association-CDC123), rs8050136 (FTO), rs10811661 and 
rs4977574 (CDKN2B), rs4402960 (IGF2BP2), rs1801282 (PPARG), rs13266634 (SLC30A8), 
rs7903146 (TCF7L2), rs1111875 (Nearest gene association-HHEX), rs5219 (KCNJ11), 
rs7754840 and rs7756992 (CDKAL1), rs10830963 (MTNR1B), rs2237892 (KCNQ1), 
rs2259816 (HNF1A), rs9818870 (MRAS), rs6922269 (MTHFDIL), rs646776 (CELSR2), 
rs17465637 (MIA3), rs2943634 (No gene association), rs17228212 (SMAD3), rs1746048 
(CXCL12). Other common genetic variants were selected based on relevant associations with 
T2DM and CVD: rs2251101 (IDE), rs10010131 (WFS1), rs11037909, rs1113132 and 
rs3740878 (EXT2), rs1800804 (MTTP), rs1053049, rs34474204, rs2016520, rs2076167 and 
rs6902123 (PPARD), rs7923837 and rs1544210 (Nearest gene association-HHEX), rs3817190 
(CAMKK2), and rs1718119, rs2230912, and rs3751143 (P2RX7), and rs7501939 and rs757210 
(HNF1B) (Table 1).  
4.2.3 Genetic analysis – Genotyping   
Genotyping is an analysis used to examine the DNA sequence at, for example specific SNP 
locations using genetic techniques such as TaqMan and Open Array). In this way we can see 
whether our patient group differs in frequency of specific SNP alleles or genotypes compared 
to controls. 
4.2.3.1 Genetic techniques and instruments 
In this thesis, two instruments have been used for genotyping. 
7900HT Fast Real-Time PCR System Instrument using allele-specific TaqMan MGB probes 
labeled with fluorescent dyes FAM and VIC (Applied Biosystems, Foster City, CA, USA), in 
accordance with the manufacturer’s instructions. Allelic discrimination was performed either 
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with the ABI PRISM 7900HT SDS and the SDS 2.2.1 program (Applied Biosystems) or with 
the later version TaqMan Genotype Software (Applied Biosystems, QuantStudio 7 Flex).  
The genotyping process was also performed on Open Array Real-Time PCR System Instrument 
(Applied Biosystems, Foster City, CA, USA). Allelic discrimination was performed with the 
TaqMan Genotype Software (Applied Biosystems). 
  31 
Table 1. SNPs tested for genetic association to metabolic risk factors in Study II and Study IV. 
Chromosome Gene SNP Allele Region   
1 CELSR2  RS646776 A/G* Near Gene-3   
1 MIA3 RS17465637 A/C* Intron   
1 NOTCH2  RS10923931 G*/T Intron   
2 No gene association RS2943634 A*/C Non coding region    
2 THADA   RS7578597 C/T* T [Thr] ⇒ A [Ala] Non-synonymous 
3 ADAMTS9-AS2 RS4607103 C*/T Intron   
3 IGF2BP2  RS4402960 G*/T Intron   
3 MRAS   RS9818870 C/T* UTR-3   
3 PPARG   RS1801282 C*/G P [Pro] ⇒ A [Ala] Non-synonymous 
4 MTTP   RS1800804 C/T* Intron   
4 WFS1  RS10010131 A/G* Intron   
6 CDKAL1 RS7754840 C/G* Intron   
6 CDKAL1   RS7756992 A/G* Intron   
6 MTHFD1L RS6922269 A*/G Intron   
6 PPARD  RS1053049 C*/T UTR-3   
6 PPARD  RS2016520 A/G* UTR-5   
6 PPARD  RS2076167 A/G* N [Asn] ⇒ N [Asn] Synonymous 
6 PPARD  RS34474204 C*/T Near Gene-5   
6 PPARD  RS6902123 C*/T Intron   
7 JAZF1 RS864745 A*/G Intron   
8 SLC30A8  RS13266634 C*/T R [Arg] ⇒ W [Trp] Non-synonymous 
9 No gene association RS10811661 C*/T Non coding region    
9 CDKN2B-AS1  RS4977574 A*/G Intron   
10 No gene association RS1111875 A*/G Non coding region    
10 No gene association RS12779790 A*/G Non coding region    
10 No gene association RS1544210 A/G* Non coding region    
10 No gene association RS1746048 C/T* Non coding region    
10  IDE RS2251101 C/T* Near Gene-3   
10 No gene association RS7923837 A/G* Non coding region    
10 TCF7L2   RS7903146 C/T* Non coding region    
11 EXT2  RS11037909 C*/T Intron   
11 EXT2  RS1113132 C*/G Intron   
11 EXT2  RS3740878 A*/G Intron   
11 KCNJ11 RS5219 C*/T K [Lys] ⇒ E [Glu Non-synonymous 
11 KCNQ1  RS2237892 C*/T Intron   
11 MTNR1B  RS10830963 C*/G Intron   
12 CAMKK2 RS3817190 A/T* T [Thr] ⇒ S [Ser] Non-synonymous 
12 No gene association RS7961581 C*/T Non coding region    
12 HNF1A   RS2259816 A/C* Intron   
12 P2RX7   RS1718119 A*/G A [Ala] ⇒ T [Thr] Non-synonymous 
12 P2RX7   RS2230912 A*/G Q [Gln] ⇒ R [Arg] Non-synonymous 
12 P2RX7   RS3751143 G/T* E [Glu] ⇒ A [Ala] Non-synonymous 
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            *Ancestral allele. Data from http://www.ncbi.nlm.nih.gov  
 
 
  
15 SMAD3 RS17228212 C/T* Intron   
16 FTO  RS8050136 A*/C Intron   
17 HNF1B RS7501939 C*/T Intron   
17 HNF1B RS757210 A*/G Intron   
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4.2.4 Statistical program and analysis 
The allelic association analyses were performed using PLINK (Center for Human Genetic 
Research, Massachusetts General Hospital, Boston, MA, USA; 
http://pngu.mgh.harvard.edu/purcell/plink/) (100). The level of nominal significance was set to 
5 percent (two-tailed). Also, IBM SPSS Statistics version 20 and 23 (IBM Corporation, 
Armonk, NY, USA) were used. The statistical power was calculated according: 
http://pngu.mgh.harvard.edu/Bpurcell/gpc/cc2.html. 
4.2.4.1 Logistic regression analysis 
Logistic regression is a statistical test that investigates the relationship between the dependent 
variable/phenotypes (i.e. elevated/normal FPG) and one or more predictors (i.e. alleles of a 
SNP). In other words, it allowed us to test the influence of alleles, such as FPG. The probability 
and effect size were observed. 
The measurement of probability (if observed relationship is occurring by chance or not) is 
given in a p-value. The statistical significance level of probability is p<0.05 – it means that the 
probability that the observation is due to chance is less than 5%. 
The odds ratio (OR) is a measure of how strong is the presence or absence of a character/trait 
(i.e. allele) between groups (i.e. elevated/normal FPG).  
In this thesis, the logistic regression analyzes were adjusted for other metabolic risk factors to 
avoid any impact on investigated genetic associations. 
4.2.4.2 Multiple test corrections 
By correcting for the number of tests done in an analysis, it is possible to reduce the incidence 
of obtaining a positive association due to chance, in addition to reducing the probability of 
getting false positive (Type I error) results. The more hypotheses there are to test, the higher the 
probability is of getting a positive result due to chance. In the genetic analyses, many tests are 
usually made, thus correction for multiple tests is recommended to minimize the incidence of 
obtaining a positive association due to chance. 
4.2.4.2.1 Bonferroni correction 
The Bonferroni correction is very strict, with significance level p<0.05, which assumes all tests 
are independent.  
4.2.4.2.2 The false discovery rate (FDR) correction 
The false discovery rate (FDR) is defined as the proportion of false positive observations 
among significant results. 
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4.2.4.2.3 Max (T) permutation 
Max (T) permutation is a less stringent multiple test correction as the permutation preserve the 
correlational structure between SNPs. 
4.2.4.3 Case-case model 
In this thesis, both case-case and case-control models have been applied. The case-case model 
is an analysis within the case group (patients). In genetic analyses use of the case-case model 
helps to reduce the clinical diversity and environmental differences between disease groups 
(101). The case-case model may represent a smaller subgroup of the population, thus more 
biologically correlated and more related to susceptibility genes than the observed population in 
general (102, 103). 
 
4.3 MATERIAL & METHODS FOR EACH STUDY 
4.3.1 Study I  
COGNITIVE MANIC SYMPTOMS IN BIPOLAR DISORDER ASSOCIATED WITH 
POLYMORPHISMS IN THE DAOA AND COMT GENES 
4.3.1.1 Subjects 
DNA from all the unrelated BD type I patients recruited were included (n=488). A four factor 
structure of the manic symptoms was previously reported in this material (109). One factor had 
high loadings of the cognitive symptoms talkativeness, distractibility, and thought disorder 
(104). Therefore, patients reported to have all these three symptoms was considered positive for 
a cognitive manic symptom (CMS) factor, and the other patients not. Of the 488 patients 215 
(44%) were positive for all three symptoms, thus showing CMS, 248 (51%) patients did not 
meet criteria for CMS and were considered as non-CMS. As population controls, 1,044 
anonymous blood donors (ABD) were used. 
4.3.1.2 Methods 
SNPs were selected for genes in the dopamine system, previously reported to influence risk for 
major psychosis, using the HapMap database (http://www.hapmap.org). In the DAOA, fifteen 
SNPs; rs3916967, rs2391191, rs1935062, rs947267, rs778294, rs778326, rs3916971, 
rs1642681, rs778293, rs1362886, rs778284, rs3918342, rs1421292, rs778308, rs778321 were 
investigated, and in the COMT, four SNPs; rs5993883, rs740601, rs4680, rs165599 were 
investigated. Hardy Weinberg p-value cut-off was p ≤ 0.05 for both cases and controls. 
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4.3.1.3 Statistical analyses 
SNPs in the DAOA and COMT were investigated for allelic association analysis in BD patients 
in two models: CMS were compared with BD patients with no CMS (case-case model), and 
BD patients with CMS were compared with ABD (case-control). Associations were corrected 
for multiple testing by the max (T) permutation in PLINK. Haploblocks, including SNPs allele-
wise nominally associated to CMS (p<0.05) or SNPs nearby (D’>0.80), were examined for 
haplotype distribution difference. Logistic regression was used to test for allele/haplotype 
associations, adjusting for gender and rs1718119 (P2RX7) (the SNPs previously published 
associations with cognitive deficit) (104). SNPs associated with CMS (p<0.05) were also tested 
for genotype association using logistic regression in dominant, recessive and codominant 
models. An allele-by-allele epistasis test was performed between the SNPs rs2391191 in DAOA 
and rs5993883 in COMT using logistic regression with a multiplicative interaction term. 
 
4.3.2 Study II  
GENES ASSOCIATED WITH INCREASED FASTING GLUCOSE IN PATIENTS 
WITH SCHIZOPHRENIA SPECTRUM DISORDERS 
4.3.2.1 Subjects  
652 schizophrenia spectrum disorder (SSD) patients were studied. Of the 652 SSD patients, 
52% were men. Mean age was 47 (±12) years. Mean waist circumference was 97 (±15) cm for 
women and 104 (±15) cm for men. 235 (36%) SSD patients were present smokers. Diabetes in 
family was reported for 150 (23%) SSD patients. Of those 652 SSD patients, 389 (60%) had 
normal FPG (<5.6 mmol/L), and 235 (36%) had increased FPG (≥5.6 mmol/L) while 28 (4%) 
was treated for diabetes. Control subjects were selected from the population based prospective 
SDPP (98) based on the frequencies of glucose level categories to represent the whole SDPP 
sample at follow up. For this genetic association study, 494 SDPP control subjects were 
selected out of which 404 individuals (82%) had normal FPG, 66 (13%) had elevated FPG 
levels, and 24 (5%) were diagnosed with T2DM.  
4.3.2.2 Methods 
SNPs tested for allele association are listed in Table 1. 
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The genotyping process was performed on Open Array Real-Time PCR System Instrument 
(Applied Biosystems, Foster City, CA, USA). Allelic discrimination was performed with the 
TaqMan Genotype Software (Applied Biosystems). 
4.3.2.3 Statistical analysis  
FPG level differences between psychosis diagnoses were investigated using ANOVA (IBM 
SPSS Staticstics 22). Any significant effects were further investigated with Fisher's least 
significant difference (LSD) post hoc analysis for multiple comparisons.  
The cut off level for FPG level was defined according to the IDF criteria. SNPs in the 
metabolic risk genes were investigated for allelic association analysis to elevated FPG in SSD 
patients in two models: case-case model - where SSD patients with increased FPG level were 
compared to SSD patients with normal FPG level, and case-control model - where SSD patients 
with increased FPG level were compared to control subjects. Logistic regression was used to 
test for allelic association, adjusted for gender, age, smoking, waist circumference, and family 
history of diabetes. Associations were corrected for multiple testing by calculating the False 
discovery rate (FDR) according to the Benjamin Hochberg method. To test the effect of 
antipsychotic drug  - on observed genetic allele associations to elevated FPG in SSD patients - 
analyses restricted to patients on clozapine (n=62) were performed. The allelic distribution for 
all SSD patients was compared to SDPP controls, adjusted for gender, age, smoking, waist 
circumference, family history of diabetes, and FPG level. All calculations were done in PLINK 
in BC|SNPmax data management and analysis. 
 
4.3.3 Study III 
MELATONIN RECEPTOR 1B GENE ASSOCIATED WITH HYPERGLYCEMIA IN 
BIPOLAR DISORDER 
4.3.3.1 Subjects 
453 BD patients, including sub-diagnosis of BD: bipolar disorder type 1 (BD-1) (82%, n=369), 
bipolar disorder type 2 (BD 2) (13%, n=59), bipolar disorder not otherwise specified (BD 
NOS) (5%, n=22), and schizoaffective disorder (SCA) (<1%, n=3) were genotyped and had the 
information on FPG levels. 280 (62%) BD patients had normal FPG (<5.6 mmol/L) and 173 
(38%) had increased FPG (≥5.6 mmol/L), whereof 7% (n=12) were treated for diabetes. 480 
SDPP controls were selected: elevated FPG (≥5.6 mmol/L) without T2DM was present in 65 
individuals (14%), and 24 (5%) were diagnosed with T2DM, 391 (81%) had normal FPG levels 
(<5.6 mmol/L). 
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4.3.3.2 Methods 
SNPs in the metabolic risk genes (selected according to the Study II: rs10010131 in wolfram 
syndrome 1 gene (WFS1), rs1718119 in purinergic receptor gene (P2RX7), rs4402960 in 
insulin-like growth factor II mRNA binding protein 2 gene (IGF2BP2), rs10923931 in 
neurogenic locus notch homolog 2 gene (NOTCH2) and rs10830963 in melatonin receptor 1B 
gene (MTNR1B) were tested for allelic association analysis to elevated FPG in BD. 
The genotyping was performed using TaqMan SNP genotyping assays on an ABI 7900 HT 
instrument (Applied Biosystems, Foster City, CA, USA). Allelic discrimination was performed 
with the TaqMan Genotype Software (Applied Biosystems, QuantStudio 7 Flex). 
4.3.3.3 Statistical analyses 
FPG level differences between BD sub-diagnoses (BD-1, BD-2, BD-NOS and SCA) were 
investigated using ANOVA, followed by testing distribution normality and the variance 
homogeneity using the Shapiro-Wilk and the Levene’s tests. All analyses were performed in 
IBM SPSS Statistics 22.  
The cut off level for FPG was defined according to the IDF. SNPs in the metabolic risk genes 
were tested for allelic association analysis to elevated FPG in BD in three models:  case-case 
model - where BD patients with increased FPG level were compared to BD patients with 
normal FPG; case-control model - where BD patients with increased FPG level were compared 
to SDPP controls, and control-control model - where SDPP controls with increased FPG were 
compared to SDPP controls with normal FPG. All analysis were preformed using logistic 
regression adjusted for gender, age and smoking. P-values were corrected for multiple testing 
according to Bonferroni (six SNPs). All calculations were performed using PLINK in 
BC|SNPmax data management and analysis. 
 
4.3.4 Study IV 
GENETIC VARIANTS OF INCREASED WAIST CIRCUMFERENCE IN PSYCHOSIS 
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4.3.4.1 Subjects 
658 SSD patients were included. Schizophrenia was the most common diagnosis (n=356, 
54%), schizoaffective disorder in 68 patients (10%), delusional disorder in 41 patients (6%), 
NOS) in 88 patients (14%), bipolar disorder in 40 patients (6%), and other psychiatric 
disorders in 65 patients (10%). 534 subjects (81%) had increased waist circumference, 254 
subjects (40%) had elevated FPG levels and 153 (23%) were positive for a family history of 
diabetes. The control sample was 494 SDPP control individuals (se Study II).  
4.3.4.2 Methods 
SNPs tested for allele association are listed in Table 1. 
Single nucleotide polymorphisms (SNPs) were genotyped using an Open Array Real-Time 
PCR System Instrument (Applied Biosystems, Foster City, CA, USA). Allelic discrimination 
was performed using TaqMan Genotype Software (Applied Biosystems). Abdominal obesity 
was measured by increased waist circumference.  
4.3.4.3 Statistical analyses 
Differences in waist circumference between psychosis diagnoses were analyzed (separately 
for men and women) in ANOVA in IBM SPSS Statistics 23 (IBM Corporation, USA).  
The cutoff level for increased waist circumference was defined according to criteria from the 
IDF: (≥80 cm women and ≥94 cm men). SNPs in the metabolic risk genes were tested for 
allelic association analysis to elevated FPG in BD in three models: case-case model - SSD 
patients with elevated waist circumference were compared to SSD patients with normal waist 
circumference; case-control model- SSD patients with elevated waist circumference were 
compared to SDPP controls, and case*-control model – all* SSD patients were compared to 
SDPP controls. Logistic regression was used in all analysis adjusted for the age, FPG, family 
history of diabetes, sex, and smoking. Additionally, the logistic regression model in the 
case*-control analysis was adjusted for the same factors and also the waist circumference. 
For multiple testing correction false discovery rate Benjamini & Hochberg (FDR BH) was 
used. In addition, to test the effect of antipsychotic treatment on nominal allelic associations 
with increased waist circumference - case-case and case-control analyses were performed 
where SSD cases were restricted to patients on clozapine (n=62). The allelic association 
analyses were performed using PLINK in BC|SNPmax data management and analysis. 
 
4.3.5 Study V 
NOTCH2 GENE ASSOCIATED WITH BIPOLAR DISORDER 
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4.3.5.1 Subjects 
453 patients diagnosed with BD, and 480 SDPP controls  (see Study III) were included. 
4.3.5.2 Methods 
Genetic variants previously associated with increased FPG among BD patients (Study III) 
and/or SSD patients (Study II) were selected. The genotyping was performed using TaqMan 
SNP genotyping assays on an ABI 7900 HT instrument (Applied Biosystems, Foster City, CA, 
USA). Allelic discrimination was performed with the TaqMan Genotype Software (Applied 
Biosystems, QuantStudio 7 Flex).  
4.3.5.3 Statistical analyses 
For nominal SNP-BD associations (p< 0.05) differences of BD sub-diagnoses (BD-1, BD-2, 
BD-NOS and SCA) among genotypes were analyzed using ANOVA using IBM SPSS 
Statistics 23 (Armonk, New York, USA). SNPs in the metabolic risk genes (Study III) were 
tested for allelic association analysis to BD - where all BD patients were compared to SDPP 
controls. The analysis was preformed using logistic regression adjusted for gender, age, FPG, 
and smoking. P-values were corrected for multiple testing according to Bonferroni. All 
calculations were performed using PLINK in BC|SNPmax data management and analysis. 
 
4.3.6 Study VI 
TROPONIN T LEVELS ASSOCIATED WITH GENETIC VARIANTS IN NOTCH2 
AND MTNR1B IN WOMEN WITH SCHIZOPHRENIA 
4.3.6.1 Subjects 
300 patients with SCZ diagnosis that had serum at the one year follow up were included in this 
study. The prevalence of a T2DM was 16% (n=18) among men and 11% (n=14) among 
women. 
4.3.6.2 Methods 
High sensitive troponin T (hsTnT) levels were measured using electrochemiluminescence 
immunoassay (ECLIA). The detection level was 5 ng/L and the reference value for hsTnT was 
≥14 ng/L, (99th percentile).  
Genetic variations previously reported in Study II to be associated with elevated FPG in 
psychosis patients were assessed: rs10010131 in WFS1, rs1718119 in P2RX7, rs4402960 in 
IGF2BP2, rs10923931 NOTCH2, and rs10830963 MTNR1B. Additionally, the genetic 
variation rs12564445 in the gene encoding troponin T (TNNT2), previously reported to be 
associated with hsTnT levels in a GWA study, was genotyped (105). Genotyping was 
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performed applying Open Array Real-Time PCR System Instrument (Applied Biosystems, 
Foster City, CA, USA) and TaqMan SNP genotyping assays on an ABI 7900 HT instrument 
(Applied Biosystems, Foster City, CA, USA). Allelic discrimination was performed using 
TaqMan Genotype Software (Applied Biosystems, QuantStudio 7 Flex). For the genotyping 
completion. 
4.3.6.3 Statistical analysis  
The relationships of hsTnT level distribution in relation to gender, age, FPG levels, smoking 
and psychosis diagnosis were analyzed, also the distributions of gender, age, and FPG levels in 
relation to genotypes were analyzed. ANOVA or unadjusted linear regression was applied. 
FPG level was categorized applying the IDF criteria. The distribution of both hsTnT levels and 
detectable hsTnT levels (≥5 ng/L) among patients with normal FPG levels and increased FPG 
levels was tested using ANOVA. For testing the association between hsTnT and TNNT2 
rs12564445, ANCOVA was used with and without adjustment for FPG levels. Moreover, to 
test the distribution of hsTnT levels between genotypes for rs10830963, rs10923931, 
rs10010131, rs1718119, rs4402960 and rs7578597 an ANCOVA adjusted for FPG and gender 
was used. A nonparametric Kruskal-Wallis test was performed for the validation of the 
ANCOVA. Also, linear relationships between hsTnT and genotypes of rs10923931 and 
rs10830963 were assessed using linear regression adjusted for FPG levels among women. 
Regression residual distributions were checked for normality. All tests were performed in IBM 
SPSS Statistics 23 (IBM Corporation, Armonk, NY, USA). 
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5 MAIN FINDINGS 
 
5.1 STUDY I 
COGNITIVE MANIC SYMPTOMS IN BIPOLAR DISORDER ASSOCIATED WITH 
POLYMORPHISMS IN THE DAOA AND COMT GENES 
CMS in patients with BD type 1 was associated in the case-case model: allele T in rs3916967 
(OR=1.39, p=0.018), and the allele G in rs2391191 (OR=1.33, p = 0.055) in the DAOA, and 
allele G in rs5993883 (OR = 1.37, p=0.025) in COMT. In the case-control model: the alleles 
T (OR=1.28, p=0.029) and G (OR=1.33, p=0.020) in the DAOA, and allele G in rs5993883 
(OR=1.45, p=0.0017), and allele A in rs165599 (OR=1.34, p=0.014) were nominally 
associated with CMS in patients with BD type 1. The haplotype consisting of the three major 
alleles TGA from SNPs rs3916967, rs2391191 and rs1935062 was associated with increased 
risk for CMS in both the case-case (OR=1.38, p=0.029) and the case-control analysis (OR = 
1.34, p = 0.0057). 
 
5.2 STUDY II 
GENES ASSOCIATED WITH INCREASED FASTING GLUCOSE IN PATIENTS 
WITH SCHIZOPHRENIA SPECTRUM DISORDERS 
The SNPs nominally associated with elevated FPG levels among SSD patients were found in 
the case-case model: the major allele G of rs4402960 in the IGF2BP2  (OR=1.39, p=0.019); 
and in the case-control model: the minor allele T of rs10923931 in the NOTCH2 (OR=1.84, 
p=0.011), the major allele T of rs7578597 in THADA (OR=1.85, p=0.014), the major allele G 
of rs10010131 in the WFS1 (OR=1.43 p=0.010), the major allele G of rs1718119 in the 
P2RX7 (OR=1.40, p=0.014), the minor allele G of rs10830963 in the MTNR1B (OR=1.51, 
p=0.0039). Genetic effect sizes were lower, although not statistically significantly, for patients 
on clozapine with elevated FPG levels compared to all patients. The genetic polymorphism in 
PPRAD was nominally associated to SSD independent of glucose level. None of the 
relationships survived correction for multiple testing. 
 
5.3 STUDY III 
MELATONIN RECEPTOR 1B GENE ASSOCIATED WITH HYPERGLYCEMIA IN 
BIPOLAR DISORDER 
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The minor allele G of the rs10830963 in MTNR1B was associated with elevated FPG levels 
among BD patients: in the case-case model (p=0.016, OR=1.49), although not significant after 
Bonferroni correction (BONF=0.066), in the control-control model (p=0.0087, OR=1.64, 
BONF=0.043), and case-control (p=0.00013, OR=1.73, BONF=0.0005). 
 
5.4 STUDY IV 
GENETIC VARIANTS OF INCREASED WAIST CIRCUMFERENCE IN PSYCHOSIS 
The genetic variants associated with increased waist circumference in patients with SSD in the 
case-case model were: the major allele C of rs17465637 in the MIA3 (OR 1.43, P = 0.027), 
the major allele C of rs9818870 MRAS (OR 1.47, P = 0.042), the major allele A of rs2230912 
in the P2RX7 (OR 1.45, P = 0.038), the major allele T of rs3817190 in CAMKK2 (OR 1.56, P 
= 0.0040), and the minor allele C of rs17228212 in SMAD3 (OR 1.45, P = 0.046). The genetic 
variants associated with increased waist circumference in patients with SSD in the case-control 
model were: the PPARD, the minor allele G of rs10830963 in the MNTR1B (OR 1.33, P = 
0.011), and the minor allele T of rs10923931 in the NOTCH2 (OR 1.47, P = 0.037). Testing 
the effect of clozapine treatment on nominal allelic associations with increased waist 
circumference - the point estimates of ORs were well within the 95% confidence intervals of 
ORs based on patients irrespectively of pharmacotherapy, except for NOTCH2. 
The genetic variants nominally associated with SSD per se, irrespective of waist circumference 
were: the major allele C of rs34474204 in the PPARD (OR 1.92, P = 0.0068), the minor allele 
G of rs10830963 in the MNTR1B (OR 1.32, P = 0.012), the minor allele T of rs10923931 in 
the NOTCH2 (OR 1.52, P = 0.021), the major allele C of rs7501939 in the HNF1B (OR 1.25, 
P = 0.027). 
 
5.5 STUDY V 
NOTCH2 GENE ASSOCIATED WITH BIPOLAR DISORDER 
The minor allele T of the rs10923931 in NOTCH2 (p=0.0040, OR=1.72, BONF=0.024) was 
associated with BD. Likewise, associations between the minor allele A of the rs1718119 in 
P2RX7 (p=0.0097, OR=0.75, BONF=0.058), and the minor allele C of the rs7578597 in 
THADA (p=0.023, OR=0.64, BONF=0.14) were found. 
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5.6 STUDY VI 
TROPONIN T LEVELS ASSOCIATED WITH GENETIC VARIANTS IN NOTCH2 
AND MTNR1B IN WOMEN WITH SCHIZOPHRENIA 
Among men (n=146), 73% (n=107) had detectable hsTnT levels (≥5 ng/L) and 17% (n=18) had 
elevated hsTnT levels (≥14 ng/L). Among women (n=154), 44% (n=68) had detectable hsTnT 
levels (≥5 ng/L) and 13% (n=9) had elevated hsTnT (≥14 ng/L). No differences in hsTnT levels 
with regard to smoking or psychosis diagnosis were detected. However, hsTnT levels were 
dependent on age, gender and FPG levels. The association between hsTnT and glucose levels 
was found also when adjusting for age and gender in a linear regression analysis 
(βstandardized=0.22, p<0.0005, R2=0.32). In addition, the hsTnT levels and detectable hsTnT 
levels (≥ 5 ng/L) were higher among patients with FPG level (≥5.6 mmol/l) compared to 
patients with normal FPG level (<5.6.mmol/L) p=0.001, F=11.34, and p=0.002, F=9.47 
respectively. Difference in hsTnT levels between genotypes of the rs10830963 in MTNR1B 
(p=0.010) was detected. The result was verified with Kruskal Wallis test (rs10830963: 
p=0.039) revealing an association of hsTnT level also with NOTCH2 rs10923931 (p=0.027). 
Moreover, a gender-specific analysis showed that these genetic associations were present only 
in women (rs10830963: p=0.026) and rs10923931: p=0.011). 
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5.7 SUMMARY OF THE FINDINGS 
 
Study I 
 
° Cognitive manic symptoms in patients with bipolar disorder type 1 are associated with  
  DAOA and COMT. 
 
	   	   	  ° Our findings are in line with the hypothesis of dopamine dysregulation contributing to 
cognitive dysfunction. 
 
Study II - V 
 
° Some SNPs associated with metabolic disorder in an otherwise healthy population are 
associated with elevated FPG and waist circumference among SSD patients and BD patients. 
 
° Metabolic risk genes associated to increased FPG in SSD patients, differs to a large extent 
from the metabolic risk genes for increased waist circumference in SSD. 
 
° The MTNR1B rs10830963 allele G–dependent vulnerability for elevated FPG levels is 
shared between SSD and BD. 
 
° Metabolic risk variant NOTCH2 rs10923931_T is associated with both SSD and BD type 1 
per se. 
 
° This may reflect:  
• increased metabolic risk allele burden among SSD and BD patients 
• increased metabolic genetic vulnerability in SSD and BD patients 
• shared genetics between T2DM, SSD and BD  
 
Study VI 
 
° hsTnT levels are associated with MTNR1B rs10830963 and NOTCH2 rs10923931 in 
women with schizophrenia. 
 
° Findings of this study may indicate metabolic genetic influences on hsTnT levels among 
women with schizophrenia. 
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6 DISCUSSION AND FUTURE PERSPECTIVES 
 
In this thesis, we provide data suggesting that genetic variants, reported to confer metabolic risk 
in the general population, are associated with metabolic risk factors in SSD and BD patients. 
Our findings further suggest that there is a partial overlap of genetic risk factors between SSD, 
BD type 1 and T2DM. 
SCZ and BD are clinically defined disorders. Neither SCZ nor BD have as yet reached such a 
level of knowledge regarding pathophysiology that they may be termed diseases. Several 
biological dysfunctions have been identified in these disorders and a number of genes have 
been associated with disease risk. These findings do not currently explain more than a fraction 
of the mechanisms behind the disorders. Furthermore, a diversity of clinical symptoms may be 
related to distinct biological processes effectively complicating the process of identifying the 
biological and genetic basis of the disorders. Studies using the case-case model of analysis, 
where specific subgroups of patients are compared to other patients, will reduce clinical 
diversity, and yield groups that have been exposed to more similar environments both as it 
relates to psychosocial stress, financial difficulties and in particular similar medication 
exposures. These similarities may also facilitate the untangling of the biological basis of 
specific symptoms or complications rather than that of the disorders themselves. This study 
approach, testing specific hypotheses in samples from selected and clinically well defined 
patients with long follow-up, is likely to generate more findings of clinical relevance than case-
control GWAS using large but more heterogeneous materials with little or no follow-up data. It 
is possible, that findings from SCZ and BP GWAS are limited because of lack of genetic 
homogeneity. To a substantial extent SCZ and BD share clinical symptoms, and also show 
similar comorbidities and mortality in metabolic disorders and CVD. There is also a substantial 
genetic overlap between SCD and BD (36) that motivates further investigations of the 
metabolic vulnerability in both SCZ and BD. Other future possible common areas of 
investigation are the search for biological and genetic factors contributing to the increased 
suicide risk, especially early in the disorders, common for both SCZ and BD. 
Patients in the studies in this thesis were recruited in a population-based way from a few 
specialized outpatient clinics where emphasis was put on including a large proportion of 
patients being followed at the respective clinic in order to have a representative sample of 
outpatient SSD and BD patients in Sweden, mainly from Stockholm County. The patients had 
been ill for a long time at sampling and those included had a well-defined diagnosis. An 
advantage with analyzing such a patient sample is that a number of co-morbidities and specific 
outcomes will have had enough time to present themselves in the sample, and thus will be large 
enough for analysis, not the least the metabolic diseases which need time to emerge, even 
though SCZ and BD patients will be affected much earlier than the general population. 
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The current Swedish population has no strong genetic boundaries, thus the individuals in this 
study were likely to come from a genetically fairly uniform population (106). Concerning 
metabolic studies, there was no difference in FPG or waist circumference between the different 
diagnoses in psychosis patients or sub-diagnosis of BD, thus findings from the present 
metabolic studies to a large extent are likely to be applicable to a broader spectrum of SSD and 
BD. Concerning the association between metabolic risk genes and BD per se, the clinic for 
affective disorder from where the vast majority of our BD sample (82%) was recruited, 
treated more severely ill BD patients (BD type 1). Thus, our results can be interpreted on a 
population level, but only for the BD type1 patients rather than BD in general. 
Regarding the control material, the presence of T2DM in the families was high, about double 
the rate reported for the general population, which probably impede detection of susceptibility 
genes for T2DM. This may have contributed to limited detection of allele associations in the 
case-control analyzes. 
The fact that most variants in this thesis had been identified in unbiased GWAS analysis or in 
functional studies and thus were not random selections mean that many of the findings can be 
considered as replications of sorts even though the clinical materials may differ in composition. 
Most SNPs did not survive multiple test corrections. However, the selection of SNPs was based 
on previous findings, thus our studies were hypothesis-driven at the gene- or SNP-level, 
effectively constituting replication studies of sorts, although in a different clinical material. For 
the metabolic studies, the effect sizes were not large, but they were however larger than in the 
population. A problem for this type of analyses is correction for multiple testing. This is 
generally required for genetic studies, and as a result it is possible that studies which are 
actually hypothesis testing are subject to too conservative corrections, resulting in disregarding 
of actual biological associations. The main weakness of the studies in this thesis would rather 
be the limited sample size, indicating a possible risk that we were not able to detect differences 
between the groups that may exist, due to insufficient sample size (low statistical power). 
MTNR1B and NOTCH2 seem to have the strongest impact in both SSD and BD, given that they 
hold for the multiple testing correction, and could conceivably be included in a panel for 
predicting the metabolic risk in SSD and BD. Since we found a genetic overlap between SSD 
and BD, a analysis of metabolic risk genes in a pooled samples of SSD and BD combined 
could be justified and be a way to increase sample size.  
Medications, in particular antipsychotics, were a limitation across the metabolic studies due 
to their known side effects to increase the risk for metabolic disorders. To investigate 
possible impact of antipsychotics on genetic associations to elevated FPG or increased waist 
circumference, genetic association analysis limited to patients on clozapine treatment was 
performed, since clozapine treatment is associated with the largest metabolic side effects. 
Since the clozapine group of patients was small, no significant p-values were expected. We 
observed a small effect size, thus suggesting a limited impact from clozapine on the observed 
  47 
genetic associations to increased FPG and increased waist circumference. 
For all metabolic studies, replication with larger sample sizes and drug-naïve patients are 
warranted to validate and confirm associations between metabolic SNPs and metabolic risk 
factors in SSD and BD patients, as well as association between metabolic SNPs, and SSD and 
BD type 1 per se. 
In Study I, the cognitive function was not measured by neuropsychological tests, and there was 
no information on cognitive function during remission. The CMS factor is a dichotomous 
categorical variable, extracted from qualitative measurements. Thus, we were not able to 
analyze cognitive function as a quantitative variable, which would be preferable. There are 
many unreplicated SNP and haplotype associations in the genetic association literature. These 
SNP or haplotype analysis results should be taken with caution, as findings need to be 
replicated. However, the support from the genetic association between CMS and SNPs in 
DAOA gives the haplotype association additional impact. Further analyses should include 
quantitative evaluation (neuropsychological tests) of cognitive function in BD, both during 
manic episodes and during remission. Assessment of psychiatric patients with different 
diagnoses with the same instrument would make it possible to analyze genetic associations with 
the DAOA and COMT genes and general cognitive functioning in psychiatry. 
The main limitation in Study VI was that this was a cross-sectional study, thus a possible 
predictive value of hsTnT levels on CVD events and deaths could not be evaluated. Prospective 
studies would be of interest to investigate if hsTnT may have predictive value of cardiovascular 
events. If hsTnT levels could be shown to be of predictive value for future CVD events, that 
might provide new tools for CVD prognosis and prevention in psychosis patients. 
As a general conclusion, the studies in this thesis identify several genetic associations covering 
clinically important aspects of SSD and BD, such as cognitive dysfunction and metabolic risk. , 
From a GWAS -perspective these studies are performed with a relatively small clinical material 
but given the stringent selection of genetic variants as well as the method of case-case analysis 
using well phenotyped patients we argue that the power is sufficient to detect at least more 
robust risk factors. Although it must be admitted that the hopes for genetic findings relevant to 
disease risk from the beginning of the GWAS era has not been fulfilled, the prospect of future 
studies along these lines hold important prospects for clinically relevant future genetic findings, 
maybe especially focusing on CVD morbidity and mortality, since excess CVD death is the 
main cause of reduced longevity of life for SCZ and BD patients. Last summer (2015), the 
United Nations unanimously adopted global development goals that, for the first time, include a 
commitment to “promote mental health and well-being” and to reduce premature deaths from 
noncommunicable diseases, including mental disorders, by one-third by 2030. To achieve this 
ambitious goal for SCZ and BD, the excess mortality in both CVD and suicide will have to be 
substantially reduced (https://sustainabledevelopment.un.org/post2015/transformingourworld).  
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